11/26
07:51 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $45.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $45.00 price target on the stock.
11/26
07:51 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $45.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $45.00 price target on the stock.
11/26
05:00 am
dyn
Rating for DYN
Medium
Report
Rating for DYN
11/26
05:00 am
dyn
Rating for DYN
Medium
Report
Rating for DYN
11/13
06:51 pm
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
High
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
11/13
06:32 pm
dyn
Rating for DYN
High
Report
Rating for DYN
11/13
10:08 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
High
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
10/24
07:15 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $35.00 price target on the stock, down previously from $43.00.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $35.00 price target on the stock, down previously from $43.00.
10/24
07:09 am
dyn
Rating for DYN
Low
Report
Rating for DYN
9/4
08:06 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Medium
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.